Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving anticoagulation therapy

Circulation

Volumn 124, Issue 23, 2011, Pages 2543-2553

  Rosenberg, Victor A ^a   Buhimschi, Irina A ^a   Lockwood, Charles J ^a   Paidas, Michael J ^a   Dulay, Antonette T ^a   Ramma, Wenda ^b   Abdel Razeq, Sonya S ^a   Zhao, Guomao ^a   Ahmad, Shakil ^b   Ahmed, Asif ^b   Buhimschi, Catalin S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

angiogenesis; anticoagulation; heparin; pregnancy; sFlt 1

Indexed keywords

AMILORIDE; ENDOGLIN; ENOXAPARIN; FMS LIKE TYROSINE KINASE 1; HEPARANASE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MONENSIN; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANTICOAGULANT THERAPY; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LONGITUDINAL STUDY; PLACENTA; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; THIRD TRIMESTER PREGNANCY; WESTERN BLOTTING;

ADULT; ANTICOAGULANTS; APOPTOSIS; CELLS, CULTURED; FACTOR XA; FEMALE; GLUCURONIDASE; HEPARIN; HUMANS; LONGITUDINAL STUDIES; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; PREGNANCY PROTEINS; RISK FACTORS; RNA, MESSENGER; THROMBOSIS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 83155161046     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.046821     Document Type: Article

References (41)

1. Lockwood CJ, Krikun G, Rahman M, Caze R, Buchwalder L, Schatz F. The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states. Semin Thromb Hemost. 2007;33:111-117. (Pubitemid 46184038)
2. Buhimschi CS, Magloire L, Funai E, Norwitz ER, Kuczynski E, Martin R, Richman S, Guller S, Lockwood CJ, Buhimschi IA. Fractional excretion of angiogenic factors in women with severe preeclampsia. Obstet Gynecol. 2006;107:1103-1113.
3. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683. (Pubitemid 38364626)
4. Signore C, Mills JL, Qian C, Yu K, Lam C, Epstein FH, Karumanchi SA, Levine RJ. Circulating angiogenic factors and placental abruption. Obstet Gynecol. 2006;108:338-344. (Pubitemid 44305675)
5. Smith GC, Crossley JA, Aitken DA, Jenkins N, Lyall F, Cameron AD, Connor JM, Dobbie R. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007;109:1316-1324. (Pubitemid 46869870)
6. Zygmunt M, Herr F, Münstedt K, Lang U, Liang OD. Angiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2003; 110:S10-S18. (Pubitemid 37074857)
7. Lockwood CJ, Krikun G, Caze R, Rahman M, Buchwalder LF, Schatz F. Decidual cell-expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis. Ann N Y Acad Sci. 2008;112:7:67-72. (Pubitemid 351563106)
8. Buhimschi CS, Schatz F, Krikun G, Buhimschi IA, Lockwood CJ. Novel insights into molecular mechanisms of abruption-induced preterm birth. Expert Rev Mol Med. 2010;12:e35.
9. Jacobsen AF, Skjeldestad FE, Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium: a register-based case-control study. Am J Obstet Gynecol. 2008;198:233.e1-233.e7.
10. Paidas MJ, Ku DH, Langhoff-Roos J, Arkel YS. Inherited thrombophilias and adverse pregnancy outcome: screening and management. Semin Perinatol. 2005;29:150-163. (Pubitemid 40909870)
11. Benedetto C, Marozio L, Tavella AM, Salton L, Grivon S, Di Giampaolo F. Coagulation disorders in pregnancy: acquired and inherited thrombophilias. Ann N Y Acad Sci. 2010;1205:106-117.
12. Silver RM, Zhao Y, Spong CY, Sibai B, Wendel G Jr, Wenstrom K, Samuels P, Caritis SN, Sorokin Y, Miodovnik M, O'Sullivan MJ, Conway D, Wapner RJ, NICHD MFMU Network. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol. 2010;115:14-20.
13. Urban G, Vergani P, Tironi R, Ceruti P, Vertemati E, Sala F, Pogliani E, Triche EW, Lockwood CJ, Paidas MJ. Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy. Int J Fertil Womens Med. 2007;52:59-67.
14. Carbone JF, Rampersad R. Prenatal screening for thrombophilias: indications and controversies. Clin Lab Med. 2010;30:747-760.
15. Kaandorp SP, Goddijn M, van der Post JA, Hutten BA, Verhoeve HR, Hamulyák K, Mol BW, Folkeringa N, Nahuis M, Papatsonis DN, Büller HR, van der Veen F, Middeldorp S. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362:1586-1596.
16. Mousa SA. Heparin and low-molecular weight heparins in thrombosis and beyond. Methods Mol Biol. 2010;663:109-132.
17. Ganapathy R, Whitley GS, Cartwright JE, Dash PR, Thilaganathan B. Effect of heparin and fractionated heparin on trophoblast invasion. Hum Reprod. 2007;22:2523-2527. (Pubitemid 47296606)
18. Haimov-Kochman R, Friedmann Y, Prus D, Goldman-Wohl DS, Greenfield C, Anteby EY, Aviv A, Vlodaversusky I, Yagel S. Localization of heparanase in normal and pathological human placenta. Mol Hum Reprod. 2002;8:566-573. (Pubitemid 34746291)
19. Sela S, Natanson-Yaron S, Zcharia E, Vlodavsky I, Yagel S, Keshet E. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res. 2011;108:1063-1070.
20. Duhl AJ, Paidas MJ, Ural SH, Branch W, Casele H, Cox-Gill J, Hamersley SL, Hyers TM, Katz V, Kuhlmann R, Nutescu EA, Thorp JA, Zehnder JL, Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol. 2007;197:457.e1-457.e21.
21. ACOG Practice Bulletin No. 113: Inherited thrombophilias in pregnancy: 2010 ACOG Committee on Practice Bulletins-Obstetrics. Obstet Gynecol. 2010;116:212-222.
22. Heydarian M, McCaffrey T, Florea L, Yang Z, Ross MM, Zhou W, Maynard SE. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta. 2009;30:250-255.
23. Denizot Y, Leguyader A, Cornu E, Laskar M, Orsel I, Vincent C, Nathan N. Release of soluble vascular endothelial growth factor receptor-1 (sFlt-1) during coronary artery bypass surgery. J Cardiothorac Surg. 2007;2:38.
24. Johnson ML, Navanukraw C, Grazul-Bilska AT, Reynolds LP, Redmer DA. Heparinase treatment of RNA before quantitative real-time RT-PCR. Biotechniques. 2003;35:1140-1142.
25. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95:884-891. (Pubitemid 39435003)
26. El Mansouri L, Bahiri R, Abourazzak FE, Abouqal R, Hajjaj-Hassouni N. Two distinct patterns of ankylosing spondylitis in Moroccan patients. Rheumatol Int. 2009;29:1423-1429.
27. Rajakumar A, Powers RW, Hubel CA, Shibata E, von Versen-Höynck F, Plymire D, Jeyabalan A. Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. Placenta. 2009;30:25-34.
28. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA. 1993;90:10705-10709. (Pubitemid 23347111)
29. Rahimi N, Golde TE, Meyer RD. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer Res. 2009;69:2607-2614.
30. Huckle WR, Roche RI. Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor. J Cell Biochem. 2004;93:120-132.
31. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676. (Pubitemid 36749215)
32. Thomas CP, Andrews JI, Liu KZ. Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. FASEB J. 2007; 21:3885-3895. (Pubitemid 350232346)
33. Carroll TY, Mulla MJ, Han CS, Brosens JJ, Chamley LW, Giles I, Pericleous C, Rahman A, Sfakianaki AK, Paidas MJ, Abrahams VM. Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am J Reprod Immunol. 2011;66:286-296.
34. Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, Marmé D. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis. 2001;4:143-154. (Pubitemid 34032700)
35. Whittle C, Gillespie K, Harrison R, Mathieson PW, Harper SJ. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin Sci (Lond). 1999;97:303-312. (Pubitemid 29425324)
36. Bose P, Black S, Kadyrov M, Weissenborn U, Neulen J, Regan L, Huppertz B. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol. 2005;192:23-30. (Pubitemid 40164214)
37. Sørensen HP, Vivès RR, Manetopoulos C, Albrechtsen R, Lydolph MC, Jacobsen J, Couchman JR, Wewer UM. Heparan sulfate regulates ADAM12 through a molecular switch mechanism. J Biol Chem. 2008; 283:31920-31932.
38. Park M, Lee ST. The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. Biochem Biophys Res Commun. 1999;264:730-734.
39. Sobel ML, Kingdom J, Drewlo S. Angiogenic response of placental villi to heparin. Obstet Gynecol. 2011;117:1375-1383.
40. Borsig L. Heparin as an inhibitor of cancer progression. Prog Mol Biol Transl Sci. 2010;93:335-349.
41. Kodama Y, Kitta Y, Nakamura T, Takano H, Umetani K, Fujioka D, Saito Y, Kawabata K, Obata JE, Mende A, Kobayashi T, Kugiyama K. Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol. 2006;48:43-50. (Pubitemid 43929228)